Status:
COMPLETED
Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
Lead Sponsor:
UConn Health
Collaborating Sponsors:
Proctor and Gamble/Aventis
Conditions:
Prostate Cancer
Eligibility:
MALE
55-85 years
Phase:
PHASE4
Brief Summary
Men treated with neoadjuvant luteinizing hormone-releasing hormone (LHRH)-agonists such as leuprolide and goserelin for prostate cancer will become hypogonadal due to hormonal suppression and demonstr...
Detailed Description
A 6-month randomized, double-blind, placebo-controlled trial was conducted, including 40 men aged ≥ 55 years receiving LHRH-agonist treatment for 6 months for locally advanced prostate cancer. Bone mi...
Eligibility Criteria
Inclusion
- Non-metastatic prostate cancer
- Men to receive Gonadotropin-releasing Hormone-agonist therapy
Exclusion
- Other cancers except skin cancer
- Evidence of metabolic bone disease
- Prior use of bisphosphonates
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00859027
Start Date
January 1 2003
End Date
February 1 2009
Last Update
May 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030